Lv3
346 积分 2025-12-13 加入
Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small cell lung cancer in a real-world setting (OSI-FACT-EP)
2个月前
已完结
Osimertinib as First-Line Treatment in Elderly Patients
2个月前
已关闭
Real-world outcomes of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC)treated with osimertinib (osi) vs. Afatinib or erlotinib
7个月前
已完结
First-line treatment in EGFR-mutated non-small cell lung cancer: brief report of an individual patient data comparison of phase 3 clinical trials
8个月前
已关闭
Characterising acquired resistance to erlotinib in non-small cell lung cancer patients
8个月前
已完结
Characterising acquired resistance to erlotinib in non-small cell lung cancer patients
8个月前
已关闭
皖公网安备34019202002308
